Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?

Steven P O’Hara, Tom H Karlsen, Nicholas F LaRusso

In primary sclerosing cholangitis (PSC), annular fibrosis around intrahepatic and extrahepatic bile ducts leads to progressive liver disease for which there is no effective therapy except liver transplantation. The concentric accumulation of connective tissue around bile ducts suggests that the cholangiocyte plays an integral role in PSC pathogenesis. However, what initiates changes in cholangiocyte phenotype and how cholangiocytes interact with cells in the peribiliary extracellular matrix like immune cells and stromal components is largely unknown. Over the last 10 years, genome-wide association studies in PSC have revealed >20 risk genes. A significant observation that can be derived from these data, which also applies to other non-Mendelian phenotypes, is that the predominant risk contribution is likely to come from one or more environmental sources, rather than the genetic aberrations. Indeed, in PSC, we estimate that <10% of the overall liability is accounted for by the genetic findings; with extrapolations into hypothetical, larger study populations, it is unlikely to exceed 30%-40%. Research dissecting the remaining environmental contribution to PSC and other complex diseases is methodologically challenging. The exposures of an organism throughout life as a whole have recently been referred to as the exposome and include a myriad of components of both the external (eg, xenobiotics) and internal (eg, gut microbes) milieu.

There is a long tradition and effective means for detecting infectious exposures in medicine. Robert Koch in the late 19th century proposed criteria to identify a disease as infectious. These included (i) the organism is regularly associated with the disease, (ii) the organism can be isolated from the diseased host and grown in culture and (iii) the disease can be reproduced when the organism is introduced into a healthy susceptible host. With the development of nucleic acid sequence-based identification of microbes, as well as the recognition that the behaviour of a particular microbe can be influenced by the community in which it resides, Koch’s original postulates have evolved. More specifically, the concept has developed to incorporate culture-independent techniques that can identify putative pathogen nucleic acid sequences or even microbe-derived products (eg, short-chain fatty acids) in association with a diseased tissue that decrease with resolution of disease and increase with clinical relapse. These ideas suggest that the scientific community should consider infectious disease causation in a broader systems biology context ‘…’ and ‘… as technology advances and new scientific discoveries are made, there must be dynamic adaptation of Koch’s postulates …’. Recent examples of an expanded paradigm thus incorporate the development of body weight-associated, IgA-associated or liver injury-associated gut microbiota in causation of obesity, IBD or alcoholic hepatitis, respectively.

There is less of a tradition and only preliminary tools to detect non-infectious environmental exposures in medicine. In light of the strong environmental component in PSC liability determined by the genetic studies, a reconsideration as to how PSC may fulfil the revised Koch’s criteria is however timely. A rationale for this proposition can be made on several sets of considerations, each of which will be addressed in this commentary. These include (i) the evolution of Koch’s postulates to account for complex exposure-driven disease; for example, obesity and IBD; (ii) similarities in cholangiocyte phenotype and downstream signalling pathways between secondary sclerosing cholangitis (SSC) due to a direct microbial infection (eg, Cryptosporidium parvum) and PSC; (iii) accumulating evidence supporting a critical role for the intestinal microbiome in the pathogenesis of PSC; (iv) a similar genetic architecture in PSC as in a prototypical exposure-driven autoimmune disease, coeliac disease; and (v) a similar genetic architecture in PSC as in cholestatic drug-induced injury.

We began studying the cholangiopathy in HIV-infected patients (a form of SSC due to biliary tract infection by opportunistic pathogens, including C. parvum) both because it was a significant clinical problem and as a result of our own clinical experience with C. parvum-induced SSC. To summarise key points from multiple in vitro and in vivo studies, we found that C. parvum, presumably via retrograde invasion of the biliary tree from the small intestine, resulted in a pro-inflammatory, activated cholangiocyte phenotype and that the process involved a number of key molecules (eg, toll-like receptors, nuclear factor KB, C/EBP Beta and NRAS). Moreover, the infection was associated with altered cholangiocyte cytokine and miRNA expression as well as inflammation and fibrosis. More recently, and relevant to this commentary, we noted that virtually all of the changes described as a result of cholangiocyte invasion by C. parvum also occurred when microbial-derived products (eg, lipopolysaccharide, flagellin) were used as an alternative to the microbe itself. Additionally, cholangiocytes in vitro develop a senescent phenotype (ie, proliferative arrest), likely involving these same pathways and processes, when chronically exposed to microbial-derived products (figure 1). Importantly, we discovered that these pathways and processes are likely operative in human PSC.

A series of divergent published and unpublished data are evolving that independently suggest, from a different perspective, microbial contributions to PSC. These data in patients with PSC include (i) expression of microbial receptors on cholangiocytes, and the occurrence of bacteremia, (iii) bacteraemia of the portal venous system, (iv) promising results of antibiotics in uncontrolled studies, and (v) genomic associations with loci implicated in host/microbiome interactions. The clinical relationship between the gut (including potentially those microbes that reside therein) and the liver in PSC was established 50 years ago with the observation that PSC frequently occurred in the setting of IBD. A series of studies recently published in Gut have demonstrated that...
Figure 1  Model of cholangiocyte activation. (A) Bile ducts are lined by cholangiocytes, specialised epithelia that under normal physiological conditions modify bile through the transport of water, ions and solutes. Portal myofibroblasts are adjacent to bile duct epithelia within the portal tract and are distinct from hepatic stellate cells which line the hepatic sinusoids; both can differentiate to matrix depositing myofibroblasts under injurious conditions. (B) Cholangiocytes exist in a harsh environment and are exposed to a variety of insults such as microbes, pathogen-associated molecular patterns, danger-associated molecular patterns, xenobiotics and bile acid-induced damage during cholestasis (from a variety of potential mechanisms, eg, oxidative stress). Recognition of these insults, for example, via pathogen recognition receptors or damage-associated molecular pattern receptors, promotes an activated cholangiocyte phenotype characterised by increased proliferation and secretion of profibrotic (eg, connective tissue growth factor) and proinflammatory (eg, interleukin 6 and 8) mediators. In this model, the activated cholangiocyte promotes hepatobiliary repair processes and recruits a variety of innate (eg, macrophages) and professional (eg, T cell) immune cells. On persistent insult, some injured cholangiocytes enter the cellular state of senescence, characterised by withdrawal from the cell cycle, and transition to a hypersecretory proinflammatory state, that is, senescence-associated secretory phenotype. On persistence, such an inflammatory/fibrotic environment will lead to sclerosing cholangitis. Reproduced with permission of Kari C. Toverud.
in Crohn’s disease? Are there different factors responsible for triggering and driving disease, respectively? At this time, answers to these questions can only be provided based on circumstantial evidence. From the genetic perspective, the strong human leucocyte antigen (HLA) class II associations (DRB1) are suggestive of at least one singular causative compound of key importance, similar to the situation in coeliac disease or drug-induced injury (figure 3). In comparison, the genetic architecture of non-autoimmune, inflammatory diseases like Crohn’s disease is largely different (figure 3), possibly due to a broader spectrum of environmental factors being involved. Further to this thinking, in coeliac disease and drug-induced liver injury, the site of metabolism is crucial for disease localisation (in coeliac disease by transglutaminase 2 in the proximal intestine, in drug-induced liver injury in the liver). In PSC, disease distribution stretches across the distal ileum throughout most of the colon (with a right-sided predominance) into the entire surface of the intrahepatic and extrahepatic bile ducts. Our knowledge of the metabolic machinery of the epithelium in the biliary fraction of this...
Figure 4  A coeliac disease model of primary sclerosing cholangitis (PSC) susceptibility. In coeliac disease, the disease-associated human leucocyte antigen (HLA) variants direct the adaptive immune response to gluten. Exposure to gluten, as well as the resulting gluten-specific adaptive immunity, respectively, is required to maintain autoantibody production and immunopathology in coeliac disease. Such observations challenge the concept that autoimmunity requires immune activation towards self-antigens. It may thus be hypothesized that the strong genetic HLA associations in PSC (and other autoimmune diseases) point to specific causal environmental exposures determined by the HLA/antigen (Ag)/T-cell receptor (TCR) interactions. Within this concept, genetic and environmental factors are co-dependent in disease causation with the implication that genetic risk factors may hold clues as to the identity of pathogenic environmental factors. For further reading, see Ref. 47. Reproduced with permission of Kari C. Toverud.

Open Access  This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

To cite  O’Hara SP, Karlsten TH, LaRusso NF. Gut Published Online First: [please include Day Month Year]. doi:10.1136/gutjnl-2017-314249

Received 31 March 2017
Revised 26 June 2017
Accepted 27 June 2017

Gut 2017;0:1–6. doi:10.1136/gutjnl-2017-314249

REFERENCES


Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?

Steven P O'Hara, Tom H Karlsen and Nicholas F LaRusso

_Gut_ published online July 21, 2017

Updated information and services can be found at: http://gut.bmj.com/content/early/2017/07/21/gutjnl-2017-314249

References

This article cites 45 articles, 11 of which you can access for free at: http://gut.bmj.com/content/early/2017/07/21/gutjnl-2017-314249#BIBL

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Open access (373)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/